Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Due Diligence who wrote (3969)	1/8/2000 6:03:00 PM
From: Howard H Bouch	Read Replies (2) \| Respond to of 4028

Shareholders update! A summary of conversation with management Cryogenics will be revamping its sight to assist in simplifying the understanding of their technology. They will also give investors the ability to sign up to receive company updates pertinent to the continual progress. As per my conversation with CYGS last Thursday, it's becoming more evident that CYGS has gone through extensive lengths to facilitate progress and prepare for the future. It was also evident that they are very excited about the future of the company and there was much that wished to be expressed but could not go into further detail at this time. Progress and forthcoming developments The alliance with CYGS and PCCA PharmGenix™ CYGS has recently re-located to a 125,000 Sq.ft facility, which allows them to take a more progressive stance in their research and development. This facility joins PCCA within close proximity of each other allowing the company's team of scientist to Enhance the efficiency of in-house testing with PCCA's team of scientist in a joint alliance to form PharmaGenix™.This is a big step in facilitating the collaborated efforts of securing a revenue stream for the company. Cyrogenics Solutions has worked diligently towards the completion of the “ Pharmagenix deal “ It is expected to be completed in the near future. In association with the completion of PharmaGenix™, additional sub-licensing agreements as well as other commercial licensing possibilities exist. Shareholders can expect a press release in regards to the development and/or finality of this project. Management is very optimistic in regards to the completion of PharmaGenix™ . The joint alliance of PharmaGenix is described as a synergistic opportunity by which CYGS will license its proprietary single stranded DNA intracellular expression vector (ssDNAev) technology to PharmaGenix™. PharmaGenix™ is the gateway from which their ingredients in combination with CYGS's technology are prepared as customized prescriptions. PCCA's 2,500 members of compounding pharmacies will in turn serve over 100,000 physicians which can then meet the needs of their patients. This project is nearing completion. Within the entity of PharmaGenix™ . CYGS and PCCA exist as a cooperative corporate enterprise, which will link traditional pharmacology with molecular biology to provide personalized healthcare products for the 21st Century. This alliance represents a progressive stance towards securing the future role of gene therapy in the evolution of modern health care. ISSUANCE OF PATENTS CYGS has confirmed the exception of some Patents that were submitted for registration. They had expected to release developments to that effect but are awaiting the official recognition that would make it possible for shareholders to confirm it's existence through public regards. We expect further details to become public upon official completion in the near future. LICENSCING DEAL WITH MAJOR BIO-MED COMPANY The question of licensing deal with a major NASDAQ company was confirmed at the December 16 shareholders meeting. The company voluntarily reiterated that fact and expressed that the deal is indeed still in the works and “ is coming to a head soon! “They also expressed that attorneys on both sides where hard at work and that the situation “looks good”. This will be announced to shareholders in the form of a press release. PUBLICATION OF MANUSCRIPT The publication of a manuscript from University studies is in the final stages of submission to a peer- reviewed journal. It is expected to be accepted !!!!! I neglected to ask if these were conclusive studies of one or several of the universities that requested beta test kits from the company beginning in April of 1999. There are numerous high profile universities that have been licensed to test CYGS's single-stranded DNA expression vector. The publication of its successful use will grant CYGS significant exposure in the industry. CYGS has conclude success of its vector in it's own testing and is awaiting conclusive results from universities for subsequent submission to industry journals as well. ADDITIONAL TESTING FOR MORE PROGRESSIVE APPLICATIONS CYGS expressed that a series of specific test in regards to their technology has evolved to a higher level but that they could not expand on the details at this time. From my past conversations with members of management, I could reasonably speculate that the next level would involve prime mates studies for the purpose of testing more progressive aspects of the successful application of CYGS's technology. This is a significant step, which upon successful completion could open the doors to humane trials for the testing various aspects of the application of their technology. This is a vital step towards the commercial applications of such technologies, many of which never make it through the fundamental trials of basic laboratory testing. As with all test phases for the refinement of such technologies, progress proceeds at its own pace. However, through my individual research of laboratory testing of gene therapy and Antisense drugs, CYGS has made major headway to even consider a next phase of testing that includes prime mates as subjects. We will keep shareholders briefed on any developments that the company wishes to confirm at the first available opportunity. CYGS CONFERENCE “OLIGO” ANNOUNCEMENT CYGS will have a major press releases in regards to a conference which will demonstrate the elements of progress and application of their technology. This conference will cater to scientist and professionals in the industry and is the stepping-stone to additional licensing of their technology to owners of patented gene sequences. The companies developments is coming in line with their ultimate goal in addressing the solution. CYGS's progress in addressing the industry's barrier is best described from an excerpt from their web site : The Solution : cygs.net The CYGS stem loop vector merges the above antisense approaches. This new technology allows an expression vector to target cells, enter the cell, and replicate if desired. The vector cassette, when inserted into the desired targeting vector, expresses sequence specific ssDNA rather than RNA. The ssDNA (1) can be regulated to express ssDNA at therapeutic but subtoxic levels, (2) is sequence specific and possesses a relatively long half-life, and (3) can be targeted to multiple sites on a target RNA or be targeted to multiple target RNAs. The results of the research will be published in the near future in a peer-reviewed journal. CYGS is negotiating to (1) acquire certain therapeutic sequences to incorporate into a product, and (2) license their enabling technology to owners of patented gene sequences. Either way, combining the above technologies promises to overcome the industry-wide obstacle currently preventing the practical application of antisense therapies. This conference is held to address the solution of Antisense delivery and gene therapy to peers in the industry. ADDITIONAL INFORMATION Recent articles of the increasing popularity of gene research and Antisense therapeutics: January 4, 2000 biz.yahoo.com Decision Resources Predicts That the Next Decade Will Be an Exciting Time for Those With a Stake in Antisense Therapeutics December 27,1999 dailynews.yahoo.com Gene Research Shares Soar on High Hopes Profile on CYGS: pennyprofiles.com A simplified explanation of CYGS's technology and forthcoming developments. Detailed specifics of CYGS and its technology can be found on their web site at: cygs.net The sheer development of the industry over the last 10 years suggest that the role of Bio-genetics, as a competing standard for the future of modern medicine is progressing. With gene therapy at the root of almost any potential viral infection or genetic inheritance of progressive diseases, we believe that CYGS is in a position to play a major role in its specific industry. It represents one of our core long-term position plays. Mic@PennyProfiles PennyProfiles- Stock hunters pennyprofiles.listbot.com pennyprofiles.com DISCLAIMER: Penny Profiles is not compensated in any way for any research or compilation of information in regards to Cryogenics Solutions, Inc., and merely distribute this information as a supplement to your own research as requested by our members. All investors and potential investors should take the time to educate themselves to the industry in general and should address and confirm any specifics by contacting the company or reviewing the company's web site at: cygs.net before making any investment decisions. Penny Profiles makes no recommendations and encourages everyone to do their own due diligence!! We are not responsible for the results of your trading decisions. Nothing in this email shall constitute a solicitation or an offer to buy or sell any securities here in. Good trading, Mic@PennyProfiles pennyprofiles.com